Navigation Links
Bedford Laboratories™ Issues Guidance on 2011 Voluntary Recall of Polymyxin B for Injection USP and Vecuronium Bromide for Injection Related to Glass Particulates
Date:1/10/2012

BEDFORD, Ohio, Jan. 10, 2012  /PRNewswire/ -- Bedford Laboratories™ today issued updated guidance on the following nationwide voluntary product recalls originally issued on August 2, 2011:

  • Polymyxin B for Injection USP, 500,000 Units per vial – NDC #55390-139-10
    Lot 1942980 – Exp. Date August 2013 and Lot 1895027 – Exp. Date June 2013
  • Vecuronium Bromide for Injection, 10 mg per vial – NDC #55390-037-10
    Lot 1865067 – Exp. Date May 2012
  • Vecuronium Bromide for Injection, 20 mg per vial – NDC #55390-039-10
    Lot 1865069 – Exp. Date February 2012

(Logo: http://photos.prnewswire.com/prnh/20070809/CLTH157LOGO )

The recalls were initiated on August 2, 2011 after the discovery of a visible glass particle in a limited number of vials within the lots listed above to the user level.   

Particulate matter in injections can be harmful when introduced into the bloodstream.  Potential adverse events after intravenous administration may include vein irritation and phlebitis, pulmonary dysfunction and granulomas, local tissue infarction, occlusion of capillaries and arteries, anaphylactic shock, and death.  The introduction of particulate matter via the intrathecal route into the cerebrospinal fluid may serve as a nidus for the development of chemical meningitis.  Introduction of a foreign body to the eye via topical or subconjuntive routes can cause corneal abrasion/laceration, lacrimal tear and general irritation.  To date, there have been no reports of adverse events for the lots being recalled.

Polymyxin B is indicated in the treatment of acute infections caused by susceptible strains of Pseudomonas aeruginosa. Polymyxin B sulfate is a drug of choice in the treatment of infections of the urinary tract, meninges, and bloodstream caused by susceptible strains of Ps. aeruginosa. It may also be used topically and subconjunctivally in the treatment of infections of the eye caused by susceptible strains of Ps. aeruginosa.

Vecuronium Bromide is indicated as an adjunct to general anesthesia, to facilitate endotracheal intubation and to provide skeletal muscle relaxation during surgery or mechanical ventilation.

Initial recall notification of the Polymyxin B for Injection and Vecuronium Bromide for Injection lots listed above were sent to impacted wholesalers and distributors on August 2, 2011 by overnight courier and arranged for return of all recalled product.  Hospitals, emergency rooms, clinics, physician offices and other healthcare facilities and providers should not use the product lots listed above for patient care and should immediately quarantine any product for return.  Should wholesalers/distributors/retailers still have product which is being recalled, they should stop use and contact Bedford Laboratories Client Services at 800.562.4797.  

Bedford Laboratories has informed the U.S. Food and Drug Administration (FDA) of its actions and is maintaining ongoing discussion with the agency.  This voluntary recall is being conducted with the knowledge of the FDA.

Hospitals, emergency rooms, clinics, physician offices and other healthcare facilities and providers, or patients with product quality compliance, medical or other questions concerning the use of the product or reasons for this recall should contact the Professional Services Department at 800.521.5169.  Any adverse reactions experienced with any of the lots reported in this release should be also reported to 800.521.5169.

Adverse reactions or quality problems experienced with the use of this product may be reported to the FDA's MedWatch Adverse Event Reporting program online, or regular mail or by fax.

As is standard practice, and as stated in the Product Package Insert, "Parenteral drug products should be inspected visually for particulate matter and discoloration prior to administration, whenever solution and container permit."

About Bedford Laboratories

Bedford Laboratories is located in Bedford, OH and began in 1993 as a division of Ben Venue Laboratories. Bedford Laboratories supplies an extensive selection of critical-care and medically necessary multisource and specialty injectable products to the healthcare marketplace. For more information, please visit http://www.BedfordLabs.com.


About Ben Venue Laboratories, Inc.

Ben Venue Laboratories, Inc. was founded in 1938 and is a leading manufacturer of highly complex, sterile injectable drug products for the global pharmaceutical industry. Ben Venue is located in Bedford, Ohio and employs more than 1,300 people.  For more information, visit www.benvenue.com.

Ben Venue is a U.S. subsidiary of Boehringer Ingelheim Corporation (Ridgefield, CT) and a member of the Boehringer Ingelheim group of companies.  Please visit http://us.boehringer-ingelheim.com.

 


'/>"/>
SOURCE Bedford Laboratories
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Bedford Laboratories(TM) To Begin Shipping Fluconazole Injection
2. Bedford Laboratories(TM) First To Manufacture Generic Indomethacin for Injection USP
3. Bedford Laboratories™ to Begin Shipping Dactinomycin for Injection USP 500 mcg (0.5 mg)
4. Bedford Laboratories™ to Begin Shipping Topotecan Hydrochloride for Injection, 4mg SD Vial
5. Sagard Capital Increases Ownership in GP Strategies by 350,000 Shares in a Private Transaction with Bedford Oak Partners, L.P.
6. The First Annual Cervical Cancer/HPV Conference Tackles Controversial Vaccine Issues and Encourages Advocacy
7. European Unions CHMP Issues Positive Opinion on PEGINTRON(TM) Combination Therapy for Retreating Hepatitis C Patients Who Failed Previous Therapy
8. European CHMP Issues Positive Opinion for ATRIPLA(R) (efavirenz 600 mg/ emtricitabine 200 mg/tenofovir disoproxil fumarate 300 mg)
9. Bayer Issues Additional Guidance to Physicians on Trasylol(R)
10. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
11. QIAGEN and Center for Molecular Medicine Create Research Collaboration for Molecular Diagnostic Markers for Breast Cancer, Other Womens Health Issues
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/10/2016)... Feb. 10, 2016  CVS Health (NYSE: CVS ... in Santa Clara County, CA , ... the Santa Clara University campus. CVS Pharmacy stores and ... patients against the disease. Students at Santa Clara University ... vaccinated. In addition, anyone who has had close contact ...
(Date:2/10/2016)... Feb. 10, 2016 Immune Pharmaceuticals Inc. (NASDAQ: ... today that it has filed a patent application directed ... cancers. --> --> ... administration of Ceplene (histamine dihydrochloride) in combination with immune ... predicting the efficacy of Ceplene and IL-2 therapy in ...
(Date:2/10/2016)... TOKYO , Feb. 10, 2016  Astellas Pharma ... , "Astellas") announced today that it has successfully completed, ... a tender offer to purchase all issued and outstanding ... OCAT, President and CEO: Paul Wotton , "Ocata") ... the stockholder in cash ("Tender Offer"). Astellas commenced the ...
Breaking Medicine Technology:
(Date:2/10/2016)... (PRWEB) , ... February 10, 2016 , ... ... four time Emmy award winner and inspirational speaker Jan Fox will serve as ... by Speaking Boldly will provide participants with tools to more effectively communicate with ...
(Date:2/10/2016)... ... 10, 2016 , ... For additional information contact Phyllis Strupp 480-488-5858 , Brain ... Age: The Ultimate Guide to Brain Training" by award-winning author Phyllis Strupp ... date is March 16, 2016. A free review copy is available to the ...
(Date:2/10/2016)... West Palm Beach, Florida (PRWEB) , ... February ... ... Golf & Country Club) announced that it has been awarded the prestigious Distinguished ... of the World award program conducted by BoardRoom magazine, one of the most ...
(Date:2/10/2016)... Middleboro, MA (PRWEB) , ... February 10, 2016 ... ... of their revolutionary, biocompatible columns and accessories. These PEEK-lined stainless steel (PLS) columns ... to provide a solution that ensures the integrity of biological samples while operating ...
(Date:2/10/2016)... ... ... Workrite Ergonomics this week announced the launch of the Conform Monitor Arm Series, ... was to develop a product from the ground up that would provide the most ... Hulsey, Product Manager for Workrite Ergonomics. “The Conform series features a wide variety ...
Breaking Medicine News(10 mins):